• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Systemic therapy of gallbladder cancer: review of first line, maintenance, neoadjuvant and second line therapy specific to gallbladder cancer

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    cco-08-04-43.pdf
    Size:
    262.5Kb
    Format:
    PDF
    Description:
    Full text, Open Access article
    Download
    Authors
    Azizi, Alexander
    Lamarca, Angela
    Valle, Juan W
    Affiliation
    Experimental Cancer Medicines Team, The Christie NHS Foundation Trust, Manchester, UK
    Issue Date
    2019
    
    Metadata
    Show full item record
    Abstract
    Gallbladder cancer is the most common malignant cancer of the biliary tract and is distinct from other forms of biliary tract cancer in several of its risk factors and molecular aberrations. Locally advanced, unresectable and metastatic gallbladder cancer is associated with a poor prognosis and systemic chemotherapy is the main form of treatment available to these patients. This review is focused on the available evidence supporting the use of first-line chemotherapy specifically for gallbladder cancer. Numerous non-randomised studies have been published and certain forms of monotherapy and combination therapy can both lead to response rates (RRs) of approximately 40% and may prove to affect overall survival, most notably a recent phase II study of triplet therapy with gemcitabine, cisplatin and nab-paclitaxel. There are however relatively few randomised phases II and III studies on which to base recommendations, but they do demonstrate significant survival advantages of gemcitabine-containing combination therapies over best supportive care and chemotherapeutic monotherapy. The ABC-02 trial established the combination of gemcitabine and cisplatin as standard therapy in 2010, but more recent phase III studies reported as conference papers may support alternative, gemcitabine-containing doublet chemotherapy regimens such as gemcitabine in combination with oxaliplatin or S1. This manuscript also highlights the available data from studies examining maintenance chemotherapy, biomarkers, neoadjuvant therapy and second line studies in gallbladder cancer; unfortunately, there is insufficient evidence to make recommendations in these regards. The prognosis for unresectable and metastatic gallbladder cancer remains poor, and biomarkers for stratifying patients to particular first line therapies are not defined. This might be improved by gallbladder cancer specific analysis and reporting, and making histological primary specific data available publicly for further analysis.
    Citation
    Azizi AA, Lamarca A, Valle JW. Systemic therapy of gallbladder cancer: review of first line, maintenance, neoadjuvant and second line therapy specific to gallbladder cancer. Chin Clin Oncol. 2019 Aug;8(4):43.
    Journal
    Chinese Clinical Oncology
    URI
    http://hdl.handle.net/10541/622106
    DOI
    10.21037/cco.2019.07.05
    PubMed ID
    31431035
    Additional Links
    https://dx.doi.org/10.21037/cco.2019.07.05
    Type
    Article
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.21037/cco.2019.07.05
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Systemic therapy for gallbladder cancer.
    • Authors: Javle M, Zhao H, Abou-Alfa GK
    • Issue date: 2019 Aug
    • Neoadjuvant chemotherapy in patients with locally advanced gallbladder cancer.
    • Authors: Sirohi B, Mitra A, Jagannath P, Singh A, Ramadvar M, Kulkarni S, Goel M, Shrikhande SV
    • Issue date: 2015
    • A review of recent data in the treatment of gallbladder cancer: what we know, what we do, and what should be done.
    • Authors: Müller BG, De Aretxabala X, González Domingo M
    • Issue date: 2014
    • A novel triplet regimen with paclitaxel, carboplatin and gemcitabine (PACCAGE) as induction chemotherapy for locally advanced unresectable non small cell lung cancer (NSCLC).
    • Authors: Schallier D, Neyns B, Fontaine C, Steene JV, De Mey J, Meysman M, De Grève J
    • Issue date: 2007 May
    • [Treatment of the unresectable non small cell lung carcinoma].
    • Authors: Spásová I
    • Issue date: 2005
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.